Resatorvid

Resatorvid
Resatorvid
Resatorvid structure.png
임상 데이터
상호Resatorvid
법적 상태
법적 상태
식별자
  • 에틸(6R)-6-[(2-클로로-4-플루오로페닐)술파모일]시클로헥센-1-카르복실레이트
CAS 번호
PubChem CID
드러그뱅크
켐스파이더
유니
첸블
CompTox 대시보드 (EPA )
화학 및 물리 데이터
공식C15H17당분이나 지방 말고도FNO4S
몰 질량361.8 g/g−1/g
3D 모델(JSmol)
  • CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)NC2=C(C=C(C=C2)F)당분이나 지방 말고도
  • InChI=1S/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-10(17)9-12(13)16/h5,7-9,14,18H2,4H2,4(4)
  • 키: LEIJTHMHDMWLJ-CQSZACIVSA-N

레조토르비드(TAK-242)는 수용체 [1]TLR4의 선택적 길항제 역할을 하는 약물이다.뇌손상 [3]항염증[2]신경보호 효과가 있으며 피부암 및 기타 암에 대한 활성을 나타내며 기존 화학요법 [4][5][6]약물과 함께 추가 치료제로서의 가능성을 보일 수 있다.

「 」를 참조해 주세요.

레퍼런스

  1. ^ Matsunaga N, Tsuchimori N, Matsumoto T, Ii M (January 2011). "TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules". Molecular Pharmacology. 79 (1): 34–41. doi:10.1124/mol.110.068064. PMID 20881006. S2CID 7818996.
  2. ^ Samarpita S, Kim JY, Rasool MK, Kim KS (January 2020). "Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug". Arthritis Research & Therapy. 22 (1): 16. doi:10.1186/s13075-020-2097-2. PMC 6979396. PMID 31973752.
  3. ^ Feng Y, Gao J, Cui Y, Li M, Li R, Cui C, Cui J (January 2017). "Neuroprotective Effects of Resatorvid Against Traumatic Brain Injury in Rat: Involvement of Neuronal Autophagy and TLR4 Signaling Pathway". Cellular and Molecular Neurobiology. 37 (1): 155–168. doi:10.1007/s10571-016-0356-1. PMID 26961544. S2CID 21583205.
  4. ^ Dickinson SE, Wondrak GT (2019). "TLR4-directed Molecular Strategies Targeting Skin Photodamage and Carcinogenesis". Current Medicinal Chemistry. 25 (40): 5487–5502. doi:10.2174/0929867324666170828125328. PMID 28847267.
  5. ^ Kashani B, Zandi Z, Karimzadeh MR, Bashash D, Nasrollahzadeh A, Ghaffari SH (December 2019). "Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers". Immunologic Research. 67 (6): 505–516. doi:10.1007/s12026-019-09113-8. PMID 32026322.
  6. ^ Zandi Z, Kashani B, Bashash D, Poursani EM, Mousavi SA, Chahardoli B, Ghaffari SH (February 2020). "The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer". Journal of Cellular Biochemistry. 121 (2): 1623–1634. doi:10.1002/jcb.29397. PMID 31535397. S2CID 202689986.